{"id":"NCT00634049","sponsor":"Astellas Pharma Inc","briefTitle":"Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi","officialTitle":"Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04-22","primaryCompletion":"2014-01-03","completion":"2016-05-05","firstPosted":"2008-03-12","resultsPosted":"2016-01-11","lastUpdate":"2024-12-11"},"enrollment":149,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Aspergillosis","Invasive Fungal Infections"],"interventions":[{"type":"DRUG","name":"isavuconazole","otherNames":["BAL8557","ASP9766"]}],"arms":[{"label":"Isavuconazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.","primaryOutcome":{"measure":"Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT).","timeFrame":"Day 42, 84 and End of Treatment (EOT [Day 180])","effectByArm":[{"arm":"mITT - Aspergillus [Renally Impaired]","deltaMin":25,"sd":null},{"arm":"mITT - Aspergillus [Not Renally Impaired]","deltaMin":50,"sd":null},{"arm":"mITT - Mucorales (Primary Therapy)","deltaMin":14.3,"sd":null},{"arm":"mITT - Mucorales (Refractory)","deltaMin":9.1,"sd":null},{"arm":"mITT - Mucorales (Intolerant)","deltaMin":0,"sd":null},{"arm":"mITT- Other Filamentous Fungi","deltaMin":47.1,"sd":null},{"arm":"mITT- Other Mould Species Only","deltaMin":28.6,"sd":null},{"arm":"mITT- Other Dimorphic Fungi","deltaMin":41.4,"sd":null},{"arm":"mITT- Other Non-Candida Yeast","deltaMin":36.4,"sd":null},{"arm":"mITT-Other Mixed Infection","deltaMin":13.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":96,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Egypt","France","Germany","India","Israel","Lebanon","Mexico","Poland","Russia","South Africa","South Korea","Thailand"]},"refs":{"pmids":["37185921","27185799","27169478","26969258"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=51"]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":59},"commonTop":["Nausea","Vomiting","Diarrhoea","Headache","Pyrexia"]}}